Seminar

Breast cancer subtypes and tumor heterogeneity

Therese Sørlie

Breast cancer comprises several molecular subtypes with differences in outcome and response to treatment. The subtypes are detected at the pre-invasive stage – Ductal Carcinoma In Situ (DCIS) -but their relevance with respect to risk of progression is unclear. The luminal subtypes (luminal A and B) account for approximately 75% of all breast cancers and are first and foremost characterized by expression of hormone receptors (estrogen receptor and/or progesterone receptor). In this presentation I will talk about two ongoing projects in our group. 1) Analysis of DCIS using spatial transcriptomics for increased insights into cancer cell and stromal cell phenotypes that might help to understand which lesions are likely to progress to invasive cancer, and 2) Role of FGFR1 in endocrine resistant breast cancer and link to innate immune response.